Related Experiment Videos
Calcium channel blockers in heart failure: help or hindrance?
M A Konstam1, J J Smith, R Patten
1Department of Medicine, New England Medical Center, Boston, Massachusetts 02111, USA.
Insights
Calcium channel blockers show potential benefits for heart failure, with amlodipine improving survival in some patients. Further research is needed to confirm these findings and understand the mechanisms involved.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Calcium channel blockers (CCBs) are investigated for cardiovascular disorders, including heart failure.
- Potential benefits include vasodilation, improved diastolic relaxation, anti-ischemic effects, and inhibition of myocyte damage.
- However, CCB use in heart failure is controversial due to potential negative inotropic effects and neurohormonal activation.
Purpose of the Study:
- To evaluate the role and safety of calcium channel blockers in managing heart failure.
- To explore the differential effects of various CCB agents based on tissue selectivity and pharmacokinetics.
- To investigate the survival benefit observed with amlodipine in heart failure patients.
Main Methods:
- Review of existing studies and clinical trials on calcium channel blockers in heart failure.
- Analysis of pharmacological properties, including tissue selectivity and pharmacokinetics of different CCB agents.
- Examination of trial data, specifically focusing on amlodipine's impact on survival in heart failure with reduced ejection fraction.
Main Results:
- Controversy exists regarding the overall benefit of CCBs in heart failure.
- Some CCBs may pose risks, potentially linked to negative inotropic action or reflex neurohormonal responses.
- Amlodipine, a newer dihydropyridine CCB, demonstrated a survival benefit in a trial involving patients with moderate to severe heart failure and reduced ejection fraction.
Conclusions:
- The efficacy and safety of CCBs in heart failure are agent-specific and depend on patient subgroups.
- Amlodipine's observed survival benefit warrants further investigation into its reproducibility and underlying mechanisms.
- Further research is essential to clarify the role of CCBs in heart failure management.
Abstract:
Since their development, calcium channel blocking agents have stimulated interest in their potential benefit for a variety of cardiovascular disorders, including heart failure. The rationale for the potential benefit of calcium channel blockers in heart failure is multi-factorial, including vasodilation, correction of perturbed diastolic relaxation, anti-ischemic action, and potential for inhibiting myocyte hypertrophy and injury. Despite these potential benefits, the degree of salutary influence has remained controversial, and a number of studies have suggested potential adverse action in patients with heart failure, perhaps linked to either negative inotropic action or to reflex neurohormonal activation. Diversity among different agents, particularly with regard to tissue selectivity and pharmacokinetics may imply substantial differences in the relative benefits and risks in various subgroups of patients with heart failure. One trial with the newer dihydropyridine agent, amlodipine, indicates benefit to survival in patients with moderate to severe heart failure and reduced ejection fraction. The reproducibility of this finding and the mechanism for this benefit deserves further investigation.